Form 4: Alector Executive Sells Shares to Cover Tax Obligations from RSU Vesting

Alector, Inc.'s President and Head of R&D, Sara Kenkare-Mitra, sold 23,890 shares of common stock on June 2, 2025, at a weighted average price of $1.3384 to satisfy tax obligations related to restricted stock unit vesting.

Summary

• Sara Kenkare-Mitra, President and Head of R&D at Alector, Inc. (ALEC), reported a transaction on June 2, 2025.
• She disposed of 23,890 shares of Alector Common Stock.
• The shares were sold at a weighted average price of $1.3384 per share, with prices ranging from $1.285 to $1.41.
• The sale was conducted to satisfy tax obligations incurred from the vesting of restricted stock units (RSUs).
• Following this transaction, Ms. Kenkare-Mitra beneficially owns 512,252 shares of Alector Common Stock.

Sentiment

Score: 5

Explanation: Neutral. The transaction is a routine tax-related sale of shares from RSU vesting and does not reflect a discretionary decision by the insider regarding the company's future prospects.

Future Outlook

NA

Management Comments

• The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units, or RSUs.

Industry Context

This Form 4 filing details a routine insider transaction for tax purposes, which is common across all industries when restricted stock units vest. It does not provide specific insights into broader industry trends for biotechnology or pharmaceuticals.

Stakeholder Impact

• Minimal direct impact on shareholders as this is a routine tax-related sale, not a discretionary one that would signal a change in insider confidence.

Key Dates

Recommendation

Keywords

Alector Inc., ALEC, Form 4, Insider Trading, Stock Sale, Restricted Stock Units, RSU Vesting, Tax Obligations, Sara Kenkare-Mitra, Biotechnology, Pharmaceuticals